NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, ...
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. today announced that the company has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA) for the ...
MOUNTAIN VIEW, Calif., December 08, 2025--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, announced the ...
NAUTILUS is the first and only pivotal clinical study to evaluate neuromodulation therapy for treating drug refractory idiopathic generalized epilepsy Neuromodulation therapy is not currently ...
NeuroPace, Inc. (NASDAQ:NPCE) released preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for drug-resistant idiopathic ...
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- NeuroPace, Inc. (NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its RNS System and ...
-- NeuroPace (NPCE) has completed the primary endpoint analysis of the one-year data from the first and only clinical study to evaluate neuromodulation therapy for idiopathic generalized epilepsy -- ...
A Cypress teen had 100 major seizures in 4 years. New epilepsy treatment is keeping her seizure-free
Peyton Johnson’s first week of college ended with her being flown back via medical helicopter to Houston for a seizure that lasted 12 hours. Johnson, a Cypress resident, had been having seizures since ...
-- 18-month data show a 77% median reduction in generalized tonic-clonic (GTC) seizures, supporting forthcoming PMA supplement submission -- -- Remains on track to submit NAUTILUS PMA Supplement to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback